☞ On deadline? For media inquiries CLICK HERE.
October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)
November 7: APC CE webinar: Preservatives in Pharmacy Compounding
November 14: ARL Bio Pharma free CE webinar: Peering Beyond the Chapter: Elevating Sterile Compounding Practices
November 15-17: Personalized Medicine Certification Course 1: Endocrinology, virtual
December 4: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)
December 5: APC CE webinar: Compounding in Special Populations
December 5: CompoundED UpDATE Regional Meeting, Scottsdale, AZ
December 13: APC Board of Directors Meeting, Las Vegas
December 13-15: A4M Longevity Fest, Las Vegas
From the manufacturing process to patient and provider challenges, this PharmExec video interview covers all things compounding.
Reuters used our comment that there's a difference between making molecules and compounding with them.
Taking a different angle, this article looked how the FDA decides when to resolve a shortage.
UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs.
APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.
The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.
Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.
This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.
Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.
It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻
The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.
FOLLOW US
